海欣股份(600851.SH)：子公司拟转让药品批文

Core Viewpoint - The company plans to transfer its drug approval documents held by its subsidiary, Xi'an Haixin Pharmaceutical Co., Ltd., to maximize asset value and recover funds due to weak profitability and high debt ratio [1] Group 1 - The company holds a 55% stake in Xi'an Haixin [1] - The decision to transfer drug approval documents comes after a comprehensive assessment of the subsidiary's financial health [1] - Xi'an Haixin will maintain its current drug production and sales operations until the transfer target is determined [1]